Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082417 | 0.98 | GAA (0.54) | GAACA1CA2CA12CA3 | |
| SCHEMBL8038985 | 0.84 | GAA (0.68) | GAACA1CA2CA12CA3 | |
| SCHEMBL547554 | 0.84 | GAA (0.68) | GAACA1CA2CA12CA3 | |
| Succinimide SCHEMBL3224337 | 0.83 | CRBN (0.46) | GAACA1CA2CA12CA3 | |
| SCHEMBL27764350 | 0.80 | GAA (0.56) | GAACA1CA2CA12CA3 | |
| SCHEMBL31313 | 0.79 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL34 | 0.79 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL1060443 | 0.79 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL1705904 | 0.79 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL11432043 | 0.79 | GAA (0.62) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013847-B1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2019-08-21 | — | — | EP | claimed |
| US-9850272-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2017-12-26 | — | — | US | claimed |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | claimed |
| EP-3013847-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | Forendo Pharma Ltd (FI) | 2016-05-04 | — | — | EP | claimed |
| CN-105518017-A | Therapeutically active estratriene thiazole derivatives as 17 beta-hydroxysteroid dehydrogenase type 1 inhibitors | FORENDO PHARMA LTD | 2016-04-20 | — | — | CN | claimed |
| US-8969546-B2 | Compounds useful in imaging and therapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2015-03-03 | — | — | US | claimed |
| WO-2014207311-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | claimed |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | ALBERTA HEALTH SERVICES (CA) | 2013-08-15 | — | — | US | claimed |
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2012-03-22 | — | — | US | claimed |
| WO-2010092111-A2 | COMPOUNDS FOR NON-INVASIVE MEASUREMENT OF AGGREGATES OF AMYLOID PEPTIDES | Technische Universität München (DE) | 2010-08-19 | — | — | WO | claimed |
| EP-2218464-A1 | Compounds for non-invasive measurement of aggregates of amyloid peptides | Technische Universität München (DE) | 2010-08-18 | — | — | EP | claimed |
| EP-1944281-A1 | 18F-labeled compounds, method for the preparation and use thereof | Technische Universität München (DE) | 2008-07-16 | — | — | EP | claimed |
| US-7265125-B2 | Neuropeptide Y antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-20050176698-A1 | Neuropeptide Y antagonists | BREU VOLKER (DE) | 2005-08-11 | — | — | US | claimed |
| EP-1318981-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-18 | — | — | EP | claimed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | claimed |
| WO-2002020488-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | claimed |
| EP-0433928-B1 | 2-Formylbenzylphosphonic acid derivatives, their preparation and their use for treatment of diseases caused by viruses | HOECHST AG (DE) | 1995-03-15 | — | — | EP | claimed |
| EP-0433928-A1 | 2-Formylbenzylphosphonic acid derivatives, their preparation and their use for treatment of diseases caused by viruses | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-26 | — | — | EP | claimed |
| EP-4747241-A1 | BENZIMIDAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4702010-A1 | PHOTOACTIVE COMPOUNDS | Merck Patent GmbH (DE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4634162-A1 | BENZIMIDAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20250223273-A1 | METHODS AND RELATED TOOLS FOR CBD CONVERSION TO THC | NIVOROZHKIN ALEX (US) | 2025-07-10 | — | — | US | disclosed |
| US-12264141-B2 | Methods and related tools for CBD conversion to THC | ARIELIUM HEALTH, LLC (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025021537-A1 | BENZIMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| CN-118778361-B | Water-soluble acrylic photoresist | 广东科优材料科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024223739-A1 | PHOTOACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| US-12018239-B2 | Laser processing machine | KATAOKA CORPORATION (JP) | 2024-06-25 | — | — | US | disclosed |
| WO-2024126407-A1 | BENZIMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| EP-3908273-B1 | METHOD AND RELATED DEVICE FOR CONVERSION OF CBD TO THC | ARIELIUM HEALTH LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-116874738-A | Polyisocyanate, preparation method thereof and application of polyisocyanate in preparation of polyurethane hard foam | 万华化学（宁波）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| CN-114786957-B | Thermosensitive recording medium | 日本制纸株式会社 | 2023-08-29 | — | — | CN | disclosed |
| CN-116655830-A | Cyclodextrin derivative and preparation method and application thereof | 桑飘飘 | 2023-08-29 | — | — | CN | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4168423-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4168424-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667230-A | Triazines with thiosulfonate end groups and process for their preparation | 弗雷克斯系统美国公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-109415353-B | Pegylated carfilzomib compounds | 美国安进公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3464277-B1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11504810-B2 | Cell processing method, laser processing machine | KATAOKA CORPORATION (JP) | 2022-11-22 | — | — | US | disclosed |
| WO-2022210798-A1 | OPTICAL SEMICONDUCTOR DEVICE, METHOD FOR MANUFACTURING SAME, SOLID-STATE IMAGING DEVICE, AND ELECTRONIC APPARATUS | 株式会社カネカ | 2022-10-06 | — | — | WO | disclosed |
| WO-2022210799-A1 | SUBSTRATE STACK, IMAGE SENSOR, AND METHOD FOR MANUFACTURING SUBSTRATE STACK | 株式会社カネカ | 2022-10-06 | — | — | WO | disclosed |
| EP-3305888-B1 | CELL TREATMENT METHOD, LASER PROCESSING MACHINE, AND CELL CULTURE VESSEL | KATAOKA CORP (JP) | 2022-09-28 | — | — | EP | disclosed |
| US-11441113-B2 | Cell treatment system | KATAOKA CORPORATION (JP) | 2022-09-13 | — | — | US | disclosed |
| CN-114907272-A | Bivalent nucleobase compound and use thereof | 卡耐基梅隆大学 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022166848-A1 | METHOD FOR SYNTHESIZING (1R,2R)-AMPP BY USING ENZYME CASCADE REACTION | 浙江普洛康裕制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2021262710-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (KY) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262708-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (KY) | 2021-12-30 | — | — | WO | disclosed |
| US-11077198-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | AMGEN INC. (US) | 2020-12-03 | — | — | US | disclosed |
| EP-3655388-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | Trucode Gene Repair, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3601237-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | Trucode Gene Repair, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3541798-A1 | 4-((6-(2-(2,4-DIFLUOROPHENYL)-1,1-DIFLUORO-2-HYDROXY-3-(5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL)PROPYL)PYRIDIN-3-YL)OXY)BENZONITRILE AND PROCESSES OF PREPARATION | Dow AgroSciences LLC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190284161-A1 | 4-((6-(2-(2,4-DIFLUOROPHENYL)-1,1-DIFLUORO-2-HYDROXY-3-(5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL)PROPYL)PYRIDIN-3-YL)OXY)BENZONITRILE AND PROCESSES OF PREPARATION | DOW AGROSCIENCES LLC (US) | 2019-09-19 | — | — | US | disclosed |
| EP-3013847-B1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2019-08-21 | — | — | EP | disclosed |
| EP-3464277-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | Amgen Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-2245038-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2018-11-07 | — | — | EP | disclosed |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | NEUBASE THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| WO-2018175927-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | TRUCODE GENE REPAIR, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3082751-B1 | TETRASUBSTITUTED PYRIMIDINE DERIVATIVES IN OXIDATIVE DYEING PREPARATIONS | HENKEL AG & CO KGAA (DE) | 2018-09-19 | — | — | EP | disclosed |
| WO-2018094127-A1 | 4-((6-(2-(2,4-DIFLUOROPHENYL)-1,1-DIFLUORO-2-HYDROXY-3-(5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL)PROPYL)PYRIDIN-3-YL)OXY)BENZONITRILE AND PROCESSES OF PREPARATION | VPS-3, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-2760868-B1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-2980085-B1 | PYRAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-9850272-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2017-12-26 | — | — | US | disclosed |
| WO-2017205392-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
| WO-2017060322-A2 | PTEFB-INHIBITOR-ADC | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| US-9617240-B2 | Pyrazole derivative | TEIJIN PHARMA LIMITED (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| EP-2734179-B1 | NOVEL OXIDATION DYE PRECURSORS | HENKEL AG & CO KGAA (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-3082751-A1 | MEANS FOR OXIDATIVE DYEING OF KERATIN FIBERS CONTAINING NOVEL TETRA-SUBSTITUTED DERIVATIVES OF PYRIMIDINE | Henkel AG & Co. KGaA (DE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016127075-A2 | TRANSGENIC PLANTS AND A TRANSIENT TRANSFORMATION SYSTEM FOR GENOME-WIDE TRANSCRIPTION FACTOR TARGET DISCOVERY | NEW YORK UNIVERSITY (US) | 2016-08-11 | — | — | WO | disclosed |
| EP-3013847-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | Forendo Pharma Ltd (FI) | 2016-05-04 | — | — | EP | disclosed |
| CN-105518017-A | Therapeutically active estratriene thiazole derivatives as 17 beta-hydroxysteroid dehydrogenase type 1 inhibitors | FORENDO PHARMA LTD | 2016-04-20 | — | — | CN | disclosed |
| WO-2016020111-A1 | NOVEL OXIDATION DYE INTERMEDIATES OF THE TYPE OF OXY-, THIO-, AND AZA-BIS-BENZENES | HENKEL AG & CO. KGAA (DE) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020110-A1 | OXY-, THIO- AND AZO- BIS-BENZENE TYPE OXIDATION DYE PRECURSORS | HENKEL AG & CO. KGAA (DE) | 2016-02-11 | — | — | WO | disclosed |
| US-20160039784-A1 | PYRAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| WO-2016020112-A1 | OXIDATION DYE PRECURSOR | HENKEL AG & CO. KGAA (DE) | 2016-02-11 | — | — | WO | disclosed |
| EP-2980085-A1 | PYRAZOLE DERIVATIVE | Teijin Pharma Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| CN-105189476-A | Pyrazole derivative | TEIJIN PHARMA LTD | 2015-12-23 | — | — | CN | disclosed |
| US-9150583-B2 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| WO-2015090292-A1 | MEANS FOR OXIDATIVE DYEING OF KERATIN FIBERS CONTAINING NOVEL TETRA-SUBSTITUTED DERIVATIVES OF PYRIMIDINE | HENKEL AG & CO. KGAA (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-9029544-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| WO-2015036550-A1 | PROCESS FOR MAKING ETORICOXIB | SYNTHON B.V. (NL) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015037675-A1 | BENZOTHIENOPYRIMIDINE COMPOUND, METHOD FOR PRODUCING SAME AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAME | 東ソー株式会社 (JP) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014207311-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | disclosed |
| EP-2536733-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2566864-B1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2760868-A1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| WO-2014095381-A1 | FUNGICIDAL IMIDAZOLYL AND TRIAZOLYL COMPOUNDS | BASF SE (DE) | 2014-06-26 | — | — | WO | disclosed |
| EP-2746277-A1 | Fungicidal imidazolyl and triazolyl compounds | BASF SE (DE) | 2014-06-25 | — | — | EP | disclosed |
| EP-2746279-A1 | Fungicidal imidazolyl and triazolyl compounds | BASF SE (DE) | 2014-06-25 | — | — | EP | disclosed |
| EP-2734179-A2 | NOVEL OXIDATION DYE PRECURSORS | Henkel AG & Co. KGaA (DE) | 2014-05-28 | — | — | EP | disclosed |
| US-8729069-B2 | Tetrahydropyridine, tetrahydroazepine, and dihydropyrrole derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-1984337-B1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2675811-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2049556-B1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2287147-B1 | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053404-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | US | disclosed |
| US-8383758-B2 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2013024130-A1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013013861-A2 | NOVEL OXIDATION DYE PRECURSORS | HENKEL AG & CO. KGAA (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-8354116-B2 | Bifunctional synthetic molecules | BIOCHEMICS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8350060-B2 | 2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative | Taisho Pharamceutical Co., Ltd. (JP) | 2013-01-08 | — | — | US | disclosed |
| EP-2536733-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8258133-B2 | 2-amino-bicyclo[3.1.0]hexane-2, 6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| WO-2012110599-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | WO | disclosed |
| EP-2123630-B1 | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-1864993-B1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| CN-102365094-A | Cyclosporin analogues for the prevention or treatment of hepatitis infections | ENANTA PHARM INC | 2012-02-29 | — | — | CN | disclosed |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120028982-A1 | 2-AMINO-BICYCLO[3.1.0]HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120004232-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-8076502-B2 | 2-amino-bicyclo(3.1.0) hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICALS CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110275700-A1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | disclosed |
| US-8039647-B2 | 2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2011101424-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-7960579-B2 | 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7951898-B2 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2011-05-31 | — | — | US | disclosed |
| US-7909978-B2 | Sulfonate salt of chromium in an anhydrous organic solvent of dimethylformamide | INFINEON TECHNOLOGIES AG (DE) | 2011-03-22 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2287147-A2 | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100298561-A1 | 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-7838619-B2 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1637517-B1 | 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-11-10 | — | — | EP | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-2245038-A1 | NEW MACROLIDES AND THEIR USE | Basilea Pharmaceutica AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| CN-101820886-A | Bifunctional synthetic molecules | BIOCHEMICS INC | 2010-09-01 | — | — | CN | disclosed |
| WO-2010092111-A2 | COMPOUNDS FOR NON-INVASIVE MEASUREMENT OF AGGREGATES OF AMYLOID PEPTIDES | Technische Universität München (DE) | 2010-08-19 | — | — | WO | disclosed |
| EP-2218464-A1 | Compounds for non-invasive measurement of aggregates of amyloid peptides | Technische Universität München (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100173895-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2010-07-08 | — | — | US | disclosed |
| US-20100150832-A1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2167104-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BioChemics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100009939-A1 | CONCURRENT DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20090306408-A1 | 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2123630-A1 | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | Taisho Pharmaceutical Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-7598408-B2 | Intermediates for synthesis of vitamin D derivatives | KNC LABORATORIES CO., LTD. (JP) | 2009-10-06 | — | — | US | disclosed |
| EP-2102212-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-09-23 | — | — | EP | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| US-7524823-B2 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| EP-2049556-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | Basilea Pharmaceutica AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1846430-B1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-7498350-B2 | Oxazolidinones as antibacterial agents | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| EP-2013172-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008156758-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BIOCHEMICS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312296-A1 | Bifunctional synthetic molecules | ADEC PRIVATE EQUITY INVESTMENTS, LLC | 2008-12-18 | — | — | US | disclosed |
| EP-1984337-A2 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080257743-A1 | METHOD OF MAKING AN INTEGRATED CIRCUIT INCLUDING ELECTRODEPOSITION OF METALLIC CHROMIUM | INFINEON TECHNOLOGIES AG (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1468036-B1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | GEN HOSPITAL CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1459765-B1 | 6-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| EP-1944281-A1 | 18F-labeled compounds, method for the preparation and use thereof | Technische Universität München (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008073956-A2 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| US-7381746-B2 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-03 | — | — | US | disclosed |
| WO-2008056187-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-05-15 | — | — | WO | disclosed |
| CN-101180306-A | Process for production of glucopyranosyloxypyrazole derivative | KISSEI PHARMACEUTICAL (JP) | 2008-05-14 | — | — | CN | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
| EP-1864993-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| EP-1846430-A1 | NEW MACROLIDES | Basilea Pharmaceutica AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-7265125-B2 | Neuropeptide Y antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007087443-A2 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070105825-A1 | Concurrent drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070021394-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7157594-B2 | 6-Fluorobicyclo[3.1.0]hexane derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060264387-A1 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2006-11-23 | — | — | US | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| EP-1679067-A1 | CONCURRENT DRUGS | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060142388-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| US-20060116401-A1 | Antibacterial compounds | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| US-20060116386-A1 | Oxazolidinones as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| US-20060116389-A1 | Antibacterial oxazolidinones | ASTRA ZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| US-20060106242-A1 | Novel intermediates for synthesis of vitamin d derivatives | KNC LABORATORIES CO., LTD. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-20060069230-A1 | Biodegradable polyketal polymers and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1637517-A1 | 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060058314-A1 | Oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20060058317-A1 | Oxazolidinone derivatives as antibacterial | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20060052399-A1 | Oxazolidinone derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | disclosed |
| EP-1598360-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF VITAMIN D DERIVATIVES | KNC Laboratories Co., Ltd (JP) | 2005-11-23 | — | — | EP | disclosed |
| EP-1581524-A2 | OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1575945-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL | Astrazeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575944-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1572687-A1 | ANTIBACTERIAL OXAZOLIDINONES | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572688-A1 | OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| EP-1567521-A1 | ANTIBACTERIAL COMPOUNDS | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1567532-A1 | OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176698-A1 | Neuropeptide Y antagonists | BREU VOLKER (DE) | 2005-08-11 | — | — | US | disclosed |
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1230224-B1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| US-6821980-B1 | Substituted 5-benzyl-2,4-diaminopyrimidines | BASILEA PHARMACEUTICA AG (CH) | 2004-11-23 | — | — | US | disclosed |
| EP-1468036-A2 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1459765-A1 | 6-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | DATTA USA (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004056819-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056818-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056817-A1 | OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056816-A1 | ANTIBACTERIAL OXAZOLIDINONES | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004048370-A1 | ANTIBACTERIAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048392-A1 | OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048350-A2 | OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | WO | disclosed |
| US-6716861-B2 | HETEROCYCLIC 1,2,4-OXADIAZOLE OR OXAZOLE RING CONTAINING PROPANOHYDROXAMIC ACIDS USEFUL AS ANTISCARRING AGENT | PFIZER, INC. | 2004-04-06 | — | — | US | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| EP-1343771-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003059988-A2 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| EP-1318981-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| EP-0793656-B1 | NOVEL BENZYL PYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | PFIZER, INC | 2002-10-17 | — | — | US | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| EP-1230224-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | disclosed |
| WO-2002020488-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001032633-A1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
| US-5763450-A | BACTERICIDES; TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0793656-A1 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016046-A2 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-05-30 | — | — | WO | disclosed |
| EP-0466982-B1 | Method for preparing solvent-resistant polymer beads | AGFA GEVAERT NV (BE) | 1995-04-12 | — | — | EP | disclosed |
| EP-0433928-B1 | 2-Formylbenzylphosphonic acid derivatives, their preparation and their use for treatment of diseases caused by viruses | HOECHST AG (DE) | 1995-03-15 | — | — | EP | disclosed |
| US-5278152-A | Aldehyde-phenylphosphonates viricides | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-11 | — | — | US | disclosed |
| US-5252445-A | Comprising a neutralized and crosslinked graft polymer of an acrylic monomer, an acrylic acid and an unsaturation halogen; spacers in a sheet or web recording material; antisticking agents; conveying | AGFA-GEVAERT, N.V. (BE) | 1993-10-12 | — | — | US | disclosed |
| EP-0466982-A1 | Method for preparing solvent-resistant polymer beads | AGFA-GEVAERT N.V. (BE) | 1992-01-22 | — | — | EP | disclosed |
| EP-0433928-A1 | 2-Formylbenzylphosphonic acid derivatives, their preparation and their use for treatment of diseases caused by viruses | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0346760-A2 | Derivatives of nigericine, methods for their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-12-20 | — | — | EP | disclosed |
| US-4670420-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1987-06-02 | — | — | US | disclosed |
| US-4330441-A | Solvent-soluble substances characterized in that water-soluble cellulose ethers are chemically bonded to water-soluble, at least predominately synthetic polymers containing acrylic units | WOLFF WALSRODE AKTIENGESELLSCHAFT (DE) | 1982-05-18 | — | — | US | disclosed |
| US-4227006-A | ANTITHROMBOTICS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1980-10-07 | — | — | US | disclosed |
| US-4168307-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1979-09-18 | — | — | US | disclosed |
| US-4154828-A | ANTITHROMBOGENIC | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1979-05-15 | — | — | US | disclosed |
| US-4139529-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1979-02-13 | — | — | US | disclosed |
| US-4125619-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1978-11-14 | — | — | US | disclosed |
| US-4066759-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-01-03 | — | — | US | disclosed |
| US-4066758-A | ANTITHROMBOTIC | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-01-03 | — | — | US | disclosed |
| US-4062963-A | N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-12-13 | — | — | US | disclosed |
| US-4049645-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-09-20 | — | — | US | disclosed |
| US-3978045-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-08-31 | — | — | US | disclosed |
| US-3978045-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | IAPP, APP, HTT | GAA 284/4885CA1 1104/4885CA2 3605/4885 |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | GAA 1141/4885CA1 1342/4885CA2 628/4885 |
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | GCGR, UGGT1, GCKR | GAA 133/4885CA1 4006/4885CA2 3972/4885 |
| US-20250223273-A1 | METHODS AND RELATED TOOLS FOR CBD CONVERSION TO THC | CNR2, CNR1, FAAH | GAA 4136/4885CA1 1384/4885CA2 2645/4885 |
| US-20060116401-A1 | Antibacterial compounds | MRPL21, NR0B2, CYP8B1 | GAA 3065/4885CA1 4010/4885CA2 4087/4885 |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | GAA 1406/4885CA1 145/4885CA2 976/4885 |
| US-20060116386-A1 | Oxazolidinones as antibacterial agents | MRPL21, MRPS23, DPP3 | GAA 832/4885CA1 2654/4885CA2 1931/4885 |
| US-20060058314-A1 | Oxazolidinone derivatives and their use as antibacterial agents | NR0B1, NR0B2, CYP8B1 | GAA 4265/4885CA1 3927/4885CA2 4326/4885 |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | GAA 435/4885CA1 3684/4885CA2 2449/4885 |
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | GAA 721/4885CA1 4879/4885CA2 4619/4885 |
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | GRM1, GRM2, GRM6 | GAA 4177/4885CA1 836/4885CA2 1004/4885 |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | GAA 1285/4885CA1 233/4885CA2 1100/4885 |
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | NR0B2, NR0B1, HRH2 | GAA 4091/4885CA1 4046/4885CA2 4387/4885 |
| US-20060058317-A1 | Oxazolidinone derivatives as antibacterial | MRPL21, XDH, PM20D2 | GAA 564/4885CA1 3583/4885CA2 2829/4885 |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, FCGRT, MAN2B1 | GAA 401/4885CA1 3661/4885CA2 4358/4885 |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | CHRM3, CHRM2, CHRM1 | GAA 4502/4885CA1 3007/4885CA2 1615/4885 |
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | CETP, MTTP, NPC1L1 | GAA 1752/4885CA1 4636/4885CA2 3433/4885 |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | GPR65, GPR119, GPR55 | GAA 3612/4885CA1 4853/4885CA2 3599/4885 |
| US-20060264387-A1 | Macrolides | PPME1, MGAM, SMPD1 | GAA 4/4885CA1 4615/4885CA2 2542/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | GAA 1406/4885CA1 145/4885CA2 976/4885 |
| US-20100009939-A1 | CONCURRENT DRUGS | CYP3A5, HPSE, SLC9A5 | GAA 3164/4885CA1 1792/4885CA2 196/4885 |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | GAA 1264/4885CA1 582/4885CA2 650/4885 |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | GAA 794/4885CA1 2958/4885CA2 2052/4885 |
| US-20050176698-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | GAA 570/4885CA1 4306/4885CA2 3311/4885 |
| US-20080312296-A1 | Bifunctional synthetic molecules | PGF, VEGFA, PTGFR | GAA 3076/4885CA1 2922/4885CA2 508/4885 |
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | GAA 452/4885CA1 468/4885CA2 587/4885 |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | GAA 1189/4885CA1 4074/4885CA2 2423/4885 |
| US-20090306408-A1 | 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative | GRIK4, GRIN2D, GRIN2C | GAA 4691/4885CA1 625/4885CA2 1014/4885 |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | GAA 2439/4885CA1 3957/4885CA2 2299/4885 |
| US-20110275700-A1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | PKLR, SORD, PKM | GAA 65/4885CA1 1504/4885CA2 3491/4885 |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | FCGRT, EPOR, MCL1 | GAA 650/4885CA1 3341/4885CA2 4367/4885 |
| US-20070021394-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | GRIN2C, GRIK4, GRIN2B | GAA 4465/4885CA1 612/4885CA2 1004/4885 |
| US-12264141-B2 | Methods and related tools for CBD conversion to THC | CNR2, CNR1, FAAH | GAA 4136/4885CA1 1384/4885CA2 2645/4885 |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | GAA 617/4885CA1 2712/4885CA2 2028/4885 |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | ALPI, TIMP3, MMP1 | GAA 2132/4885CA1 127/4885CA2 184/4885 |
| US-20100173895-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | PARP1, PARP2, PARP15 | GAA 1953/4885CA1 4864/4885CA2 4464/4885 |
| US-20100150832-A1 | BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE | PKLR, SORD, PKM | GAA 65/4885CA1 1504/4885CA2 3491/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | GAA 887/4885CA1 398/4885CA2 490/4885 |
| US-11077198-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | GAA 650/4885CA1 3341/4885CA2 4367/4885 |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | GAA 1141/4885CA1 1342/4885CA2 628/4885 |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | PAICS, MPI, ALDOA | GAA 476/4885CA1 1561/4885CA2 3613/4885 |
| US-20060106242-A1 | Novel intermediates for synthesis of vitamin d derivatives | VDR, CYP24A1, CYP2R1 | GAA 4028/4885CA1 1308/4885CA2 840/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | GAA 2575/4885CA1 4605/4885CA2 3891/4885 |
| US-20190284161-A1 | 4-((6-(2-(2,4-DIFLUOROPHENYL)-1,1-DIFLUORO-2-HYDROXY-3-(5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL)PROPYL)PYRIDIN-3-YL)OXY)BENZONITRILE AND PROCESSES OF PREPARATION | PDXK, PYM1, PF4 | GAA 3066/4885CA1 4408/4885CA2 4492/4885 |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | IL4, IL5, IL2 | GAA 603/4885CA1 1501/4885CA2 264/4885 |
| US-20160039784-A1 | PYRAZOLE DERIVATIVE | XDH, NLRP3, NLRP1 | GAA 1230/4885CA1 1430/4885CA2 394/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | GAA 1285/4885CA1 233/4885CA2 1100/4885 |
| US-20070105825-A1 | Concurrent drugs | CYP3A5, HPSE, SLC9A5 | GAA 3164/4885CA1 1792/4885CA2 196/4885 |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | ALPI, TIMP3, MMP1 | GAA 2132/4885CA1 127/4885CA2 184/4885 |
| US-20020052356-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | GAA 570/4885CA1 4306/4885CA2 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.